Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron | B3 | Healthcare | Biotechnology & Medical Research | R$343.99B | 13.4x | 1.3 | R$55.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings BDR | B3 | Healthcare | Biotechnology & Medical Research | R$155.11B | 19.8x | 6.77 | R$220 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | B3 | Healthcare | Biotechnology & Medical Research | R$151.43B | -44.4x | -1.39 | R$56 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | B3 | Healthcare | Biotechnology & Medical Research | R$138.46B | -31.1x | 0.18 | R$35.88 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | B3 | Healthcare | Biotechnology & Medical Research | R$58.44B | -2.8x | -0.11 | R$7.52 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | B3 | Healthcare | Biotechnology & Medical Research | R$54.22B | -22.1x | -0.92 | R$54.36 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioTechne | B3 | Healthcare | Biotechnology & Medical Research | R$46.86B | 50.3x | -1.71 | R$9.85 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomm On | B3 | Healthcare | Biotechnology & Medical Research | R$1.20B | -15x | -0.45 | R$9.46 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |